Skip to main content

A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498.

Publication ,  Conference
Sampson, JH; Omuro, AMP; Preusser, M; Lim, M; Butowski, NA; Cloughesy, TF; Strauss, LC; Latek, RR; Paliwal, P; Weller, M; Reardon, DA
Published in: Journal of Clinical Oncology
May 20, 2016

Duke Scholars

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2016

Volume

34

Issue

15_suppl

Start / End Page

TPS2079 / TPS2079

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sampson, J. H., Omuro, A. M. P., Preusser, M., Lim, M., Butowski, N. A., Cloughesy, T. F., … Reardon, D. A. (2016). A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498. In Journal of Clinical Oncology (Vol. 34, pp. TPS2079–TPS2079). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2016.34.15_suppl.tps2079
Sampson, John H., Antonio Marcilio Padula Omuro, Matthias Preusser, Michael Lim, Nicholas A. Butowski, Timothy Francis Cloughesy, Lewis C. Strauss, et al. “A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498.” In Journal of Clinical Oncology, 34:TPS2079–TPS2079. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.tps2079.
Sampson JH, Omuro AMP, Preusser M, Lim M, Butowski NA, Cloughesy TF, et al. A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. TPS2079–TPS2079.
Sampson, John H., et al. “A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498.Journal of Clinical Oncology, vol. 34, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2016, pp. TPS2079–TPS2079. Crossref, doi:10.1200/jco.2016.34.15_suppl.tps2079.
Sampson JH, Omuro AMP, Preusser M, Lim M, Butowski NA, Cloughesy TF, Strauss LC, Latek RR, Paliwal P, Weller M, Reardon DA. A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. TPS2079–TPS2079.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2016

Volume

34

Issue

15_suppl

Start / End Page

TPS2079 / TPS2079

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences